EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sex- and Cancer-Related Differences in Reported Adverse Reactions with Pembrolizumab Monotherapy: A Real-World Pharmacovigilance Analysis from EudraVigilance

Giuliana Ciappina, Francesca Basile, Cristiana La Russa, Mariapia Marafioti, Giordana Di Mauro, Dalila Incognito, Enrica Maiorana, Vincenzo Quagliariello, Patrizia Carroccio, Alessio Ardizzone, Alessandro Ottaiano, Gaetano Facchini und 9 weitere

Cancers · 10.11.2026 · 18 (22) · 3602

DOI: 10.3390/cancers18223602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 10.11.2026. Verfasst von Giuliana Ciappina und 20 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Sex-related differences in reporting of adverse reactions to pembrolizumab remain incompletely characterized across tumour types. We investigated the associations of sex, age, and tumour histotype with organ-specific reporting patterns and adverse-reaction reporting multiplicity in EudraVigilance.

Methods

We retrospectively analysed individual case safety reports (ICSRs) involving pembrolizumab monotherapy from 1 January to 31 December 2025. Suspected adverse drug reactions (ADRs) were grouped by MedDRA System Organ Class (SOC); reporting multiplicity was defined as one versus at least two ADRs per ICSR. Associations were examined using chi-square tests and Cramér’s V, with Bonferroni correction across nine SOCs and multivariable logistic regression adjusted for age and tumour histotype.

Results

Among 8488 eligible ICSRs, sex was recorded in 7991, age in 6941, and tumour type was evaluable in 6482 reports across 14 categories. Reporting multiplicity did not differ by sex (p = 0.110). In unadjusted analyses, women had higher reporting proportions of endocrine (18.4% vs. 12.4%) and blood and lymphatic disorders (13.4% vs. 9.5%), whereas men had higher proportions of respiratory (12.4% vs. 7.0%) and cardiac disorders (13.9% vs. 11.5%); all four associations met the Bonferroni threshold. None remained significant after adjustment for age and tumour histotype. Reporting multiplicity differed modestly by age (p = 0.026) and by tumour type (p = 0.016), with small effect sizes.

Conclusions

Sex-related organ-specific differences in spontaneous reporting may partly reflect tumour-type composition rather than independent sex effects. These hypothesis-generating signals require confirmation in prospective studies with treatment-exposure denominators.

Zitieren

APA

Ciappina, G., Basile, F., Russa, C. L., Marafioti, M., Mauro, G. D., Incognito, D., Maiorana, E., Quagliariello, V., Carroccio, P., Ardizzone, A., Ottaiano, A., Facchini, G., Maurea, N., Toscano, E., Luca, F. D., Esposito, E., Minutoli, F., Zuccalà, V., Ieni, A., …, & Berretta, M. (2026). Sex- and Cancer-Related Differences in Reported Adverse Reactions with Pembrolizumab Monotherapy: A Real-World Pharmacovigilance Analysis from EudraVigilance. Cancers, 18(22), 3602. https://doi.org/10.3390/cancers18223602

Vancouver

Ciappina G, Basile F, Russa CL, Marafioti M, Mauro GD, Incognito D, et al. Sex- and Cancer-Related Differences in Reported Adverse Reactions with Pembrolizumab Monotherapy: A Real-World Pharmacovigilance Analysis from EudraVigilance. Cancers. 2026;18(22):3602. doi:10.3390/cancers18223602

BibTeX
@article{Ciappina2026,
  author = {Ciappina, Giuliana and Basile, Francesca and Russa, Cristiana La and Marafioti, Mariapia and Mauro, Giordana Di and Incognito, Dalila and Maiorana, Enrica and Quagliariello, Vincenzo and Carroccio, Patrizia and Ardizzone, Alessio and Ottaiano, Alessandro and Facchini, Gaetano and Maurea, Nicola and Toscano, Enrica and Luca, Fabiola De and Esposito, Emanuela and Minutoli, Fabio and Zuccalà, Valeria and Ieni, Antonio and Franchina, Tindara and Berretta, Massimiliano},
  title = {Sex- and Cancer-Related Differences in Reported Adverse Reactions with Pembrolizumab Monotherapy: A Real-World Pharmacovigilance Analysis from EudraVigilance},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3602},
  doi = {10.3390/cancers18223602}
}
Kostenlos starten →